These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 32974146)

  • 1. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma.
    Yin W; Jiang X; Tan J; Xin Z; Zhou Q; Zhan C; Fu X; Wu Z; Guo Y; Jiang Z; Ren C; Tang G
    Front Oncol; 2020; 10():1409. PubMed ID: 32974146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
    Zhang C; Li Z; Qi F; Hu X; Luo J
    Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
    Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
    Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of tumor mutation burden and the relationship between tumor mutation burden and immune infiltration in
    Wen Y; Ouyang D; Chen Q; Zeng L; Luo N; He H; Anwar M; Qu L; Zou Q; Yi W
    Gland Surg; 2022 Jan; 11(1):100-114. PubMed ID: 35242673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma.
    Kang K; Xie F; Mao J; Bai Y; Wang X
    Front Oncol; 2020; 10():573141. PubMed ID: 33072607
    [No Abstract]   [Full Text] [Related]  

  • 6. Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma.
    Deng X; Lin D; Chen B; Zhang X; Xu X; Yang Z; Shen X; Yang L; Lu X; Sheng H; Yin B; Zhang N; Lin J
    Front Oncol; 2019; 9():1310. PubMed ID: 31824866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying
    Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
    PeerJ; 2023; 11():e16618. PubMed ID: 38099311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer.
    Zhou Z; Xie X; Wang X; Zhang X; Li W; Sun T; Cai Y; Wu J; Dang C; Zhang H
    Front Genet; 2021; 12():623424. PubMed ID: 33664769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRLHR Immune Genes Associated With Tumor Mutation Burden can be Used as Prognostic Markers in Patients With Gliomas.
    Liu Y; Xiang J; Peng G; Shen C
    Front Oncol; 2022; 12():620190. PubMed ID: 35800054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
    Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
    Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma.
    Xu S; Wang Z; Ye J; Mei S; Zhang J
    Front Oncol; 2021; 11():729103. PubMed ID: 34568059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and validation of a tumor mutational burden and immune-related prognostic model for predicting the prognosis of patients with lung squamous cell carcinoma.
    Zhou Y; Xu M; Zhao K; Liu B
    J Thorac Dis; 2023 Mar; 15(3):1319-1334. PubMed ID: 37065576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel risk score model based on fourteen chromatin regulators-based genes for predicting overall survival of patients with lower-grade gliomas.
    Zhang Y; Yu B; Tian Y; Ren P; Lyu B; Fu L; Chen H; Li J; Gong S
    Front Genet; 2022; 13():957059. PubMed ID: 36246611
    [No Abstract]   [Full Text] [Related]  

  • 14. Correlations between tumor mutation burden and immune infiltrates and their prognostic value in pancreatic cancer by bioinformatic analysis.
    Cai Y; Wang X; Wang N; Wu J; Ma L; Xie X; Zhang H; Dang C; Kang H; Zhang S; Zhou Z
    Life Sci; 2021 Jul; 277():119505. PubMed ID: 33872662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression and immune infiltration in melanoma patients with different mutation burden.
    Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
    BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor mutational burden is associated with poor outcomes in diffuse glioma.
    Wang L; Ge J; Lan Y; Shi Y; Luo Y; Tan Y; Liang M; Deng S; Zhang X; Wang W; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Mar; 20(1):213. PubMed ID: 32164609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
    Lin J; Lin Y; Huang Z; Li X
    Comput Math Methods Med; 2020; 2020():8836493. PubMed ID: 33273963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma.
    Xie F; Bai Y; Yang X; Long J; Mao J; Lin J; Wang D; Song Y; Xun Z; Huang H; Yang X; Zhang L; Mao Y; Sang X; Zhao H
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107135. PubMed ID: 33189609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-Related Gene SERPINE1 Is a Novel Biomarker for Diffuse Lower-Grade Gliomas
    Huang X; Zhang F; He D; Ji X; Gao J; Liu W; Wang Y; Liu Q; Xin T
    Front Oncol; 2021; 11():646060. PubMed ID: 34094933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.